Ausgabe 3/2015
Inhalt (14 Artikel)
Treatment of advanced thyroid cancer: role of molecularly targeted therapies
Lorinda L. Covell, Apar Kishor Ganti
The route to personalized medicine in bladder cancer: where do we stand?
Francesco Massari, Chiara Ciccarese, Matteo Santoni, Matteo Brunelli, Alessandro Conti, Alessandra Modena, Rodolfo Montironi, Daniele Santini, Liang Cheng, Guido Martignoni, Stefano Cascinu, Giampaolo Tortora
Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals
Onat Kadioglu, Jingming Cao, Mohamed E. M. Saeed, Henry Johannes Greten, Thomas Efferth
Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma
Jianhong Li, Cynthia L. Jackson, Dongfang Yang, Lelia Noble, Michael Wheeler, Dolores MacKenzie, Temitope Adegun, Ali Amin
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC)
C. W. Kwok, O. Treeck, S. Buchholz, S. Seitz, O. Ortmann, J. B. Engel
Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer
Feby Ingriani Mardjuadi, Javier Carrasco, Jean-Charles Coche, Christine Sempoux, Anne Jouret-Mourin, Pierre Scalliet, Jean-Charles Goeminne, Jean-François Daisne, Thierry Delaunoit, Peter Vuylsteke, Yves Humblet, Nicolas Meert, Marc van den Eynde, Anne Moxhon, Karin Haustermans, Jean-Luc Canon, Jean-Pascal Machiels
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry
Katerina Kubackova, Z. Bortlicek, T. Pavlik, B. Melichar, Z. Linke, P. Pokorna, R. Vyzula, J. Prausova, T. Buchler
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition
Simona Coco, Anna Truini, Angela Alama, Maria Giovanna Dal Bello, Roberta Venè, Anna Garuti, Enrico Carminati, Erika Rijavec, Carlo Genova, Giulia Barletta, Claudio Sini, Alberto Ballestrero, Francesco Boccardo, Francesco Grossi
Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack
Marc Cinci, Srinivas Mamidi, Wenhan Li, Volker Fehring, Michael Kirschfink
Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?
M. A. Allard, R. Saffroy, P. Bouvet de la Maisonneuve, L. Ricca, N. Bosselut, J. Hamelin, E. Lecorche, M. A. Bejarano, P. Innominato, M. Sebagh, R. Adam, J. F. Morère, A. Lemoine
Everolimus in patients with metastatic renal cell carcinoma previously treated with bevacizumab: a prospective multicenter study CRAD001LRU02T
Ilya Tsimafeyeu, Anton Snegovoy, Sergei Varlamov, Sufia Safina, Ilya Varlamov, Ludmila Gurina, Ludmila Manzuk
Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib
Yi Ling Teo, Xiu Ping Chue, Noan Minh Chau, Min-Han Tan, Ravindran Kanesvaran, Hwee Lin Wee, Han Kiat Ho, Alexandre Chan
Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle
Anna M. J. Thijs, Saloua El Messaoudi, Johanna C. M. Vos, Alfons C. Wouterse, Vivienne Verweij, Henry van Swieten, Carla M. L. van Herpen, Winette T. A. van der Graaf, Luc Noyez, Gerard A. Rongen